Board of Directors

Se Hwan Yang, Ph.D. – Chief Executive Officer

Dr. Se Hwan Yang founded NeoImmuneTech in January 2014. Dr. Yang has created several intellectual-property protected inventions, including the hyFc® platform technology and Hyleukin-7 drug candidate. Prior to his position at NIT, Dr. Yang was Genexine’s Head of Research Institute and Business division from 2007 to 2014 and has served as a BOD member of Genexine. He received his Ph.D. from Pohang University of Science and Technology and has over 20 years of experiences of research, product development and business in life sciences, including molecular biology, immunology and protein engineering.

Richard Kang, Ph.D. – Chief Operating Officer / Chief Financial Officer

Dr. Richard Kang joined NeoImmuneTech’s Board of Directors in January 2014. Dr. Kang is an active serial entrepreneur. He has served as Board of Directors and Chief Operating Officer at NeuroBo Pharmaceuticals, Inc. and has served as Board of Directors and Chief Executive Officer at JK BioPharma Solutions, Inc. He had held several advisory positions in government-related organizations and industry. Dr. Kang holds B.S. and M.S. from Seoul National University in Korea and Ph.D. from the University of Edinburgh in UK and was a postdoctoral visiting fellow at National Cancer Institute, NIH.

Junghee Lim

Mr. Lim received his BS in Biotechnology from Yonsei University and graduated his master’s degree in B-cell lg alpha signal transduction in 1998. In 2000, he joined KTB network and was involved in bio-related investment and moved to IsuAbxis. He was involved in strategic planning and patent related work in the development of the first biosimilar antibody, Clotinab®. Since 2009, he has been in charge of bio-investment business at Intervest. As a manager, he invested in Genexine, Dinona, Drtech, Toolgen, and Orum Therapeutics.

Jae Joon Kim

Mr. Kim is currently a Director of the Healthcare Investment Division of Korea-based Mirae Asset Venture Investments (Mirae Asset). Since 2009, he has been leading the Venture Investment Division of Mirae Asset and has successfully listed over 20 companies on the NASDAQ, KOSDAQ and KONEX stock market exchanges. He currently manages an equity investment portfolio comprised of more than 40 biopharmaceutical and medical diagnostics companies worldwide. Mr. Kim earned a Master’s Degree from the Graduate School of Medicine, Korea University and a Bachelor of Science degree from Korea University.

Kyu Don Kim, Ph.D.

Dr. Kim joined Genexine in 2015 as Head of Business Development. In 2016, he was appointed Chief Operating Officer and has been responsible for the operating of the company’s administration and alliance management of JV partners in the China, Indonesia, Turkey and Korea. Prior to joining Genexine, Dr. Kim was Chief Executive Officer at Chong Kun Dang, Vice President of Samsung Electronics, and Vice president of LG Life Sciences. Dr. Kim received his BS in Biochemistry from the Yonsei University, Ph.D. in Biochemistry from the Northern Illinois University and performed postdoctoral work at the Microbiology Department, University of Florida at Gainesville. He also received MBA degree from Sogang Business School.

Youngtae Hong, Ph.D.

Dr. Hong has 13 years of industrial experiences including research and clinical development in biotechnology area. He is currently managing the PEF fund in QUAD investment management since 2016. Before joining QUAD, he worked as head of business development at ViroMed. He received his B.S. in Microbiology and M.S. and Ph.D. in Genetic Engineering from Seoul National University.